Alcon's Q4 Earnings Surpass Expectations, Proposes CHF 0.20/Share Dividend


Alcon AG ALC reported Q4 FY21 sales of $2.13 billion, +11% Y/Y on a reported basis and +13% on a constant currency (cc) basis, beating the consensus of $2.04 billion.

  • Eye care markets in the fourth quarter reflected the recovery in the U.S. and the continuing recovery internationally from the COVID-19 pandemic.
  • It reported a core EPS of $0.56, surpassing the Wall Street estimate of $0.49, and higher than $0.41 a year ago.
  • Related: Alcon Strengthens Surgical Glaucoma Portfolio With $475M Ivantis Deal.
  • Surgical net sales increased 12% (14% cc) to $1.26 billion. Implantables growth reflected market improvements and ongoing adoption of advanced technology intraocular lenses, led by the launch of Vivity. 
  • Consumables growth primarily reflected market improvements. Growth in equipment/other was primarily driven by cataract equipment.
  • Vision Care's net sales of $0.9 billion increased 10%, or 12% on a constant currency basis. Contact lens sales benefited from growth in silicone hydrogel (SiHy) contact lenses and continuing recovery in international markets.
  • Dividend: The company's board proposed a CHF 0.20 per share dividend. The shareholders will vote on this proposal at the 2022 Annual General Meeting on April 27.
  • Guidance FY22: Alcon forecasts FY22 sales of $8.7 billion - $8.9 billion, above the consensus of $8.63 billion.
  • It expects FY22 core EPS of $2.35 - $2.45, better than the consensus of $2.41.
  • Price Action: ALC shares are up 1.60% at $80.09 on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidanceDividendsHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!